Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Strategy

Industry Veteran Haggar To Lead Private Equity-Backed Zentiva From Next Month

Only four months after it was carved out from Sanofi to become an independent company, Prague-based Zentiva has announced fresh leadership in the form of Nick Haggar, the 30-year industry veteran and former president of Medicines of Europe.

Appointments Europe

Pfizer Axes Staff And Five Pre-Clinical Biosimilars To Fund Late-Stage Innovative Programs

With an eye on moving to market its broad pipeline of innovative brands, Pfizer has cut development of five early-stage biosimilar assets, in a decision that will affect 150 staff. The move is not reflective of Pfizer's overall commitment to biosimilars, the US-based company maintains.

Strategy Biosimilars

Amneal Eyes Generic Injectables Deals, While Competition Bites Sooner Than Anticipated

A strengthened cash position has provided Amneal the chance to seek inorganic opportunities to bolster its growing presence in injectables. The US-based, US-centric company is looking to grow its operations, having been surprised in recent weeks by generic competition to its most lucrative generic assets.

Strategy Pricing Debate

Coherus BioSciences Outlines ‘Very Different Approach’ And Raises Another US$75m To Launch Udenyca

Just days after it began selling the second biosimilar pegfilgrastim product in the US, and the company’s first, Coherus BioSciences’ management took to the J.P. Morgan Healthcare Conference to explain how the company is set apart from rival Mylan. Through debt financing, the California-based player has also just grabbed a further US$75 million to fuel the biosimilar’s launch.

Biosimilars Strategy

Mallinckrodt Details Timeline And Financing For Spinning Off Generics Business

Under plans announced last December, Mallinckrodt is to spin off its specialty generics and API business; at the recent Annual J.P. Morgan Healthcare Conference, management painted a timeline to completing the project and provided details on the business’ financing and growth prospects.

Strategy Deals

Akorn’s Chief Operating Officer Heads For The Exit Days Into Doug Boothe’s Tenure

A month after a court ruled that Fresenius Kabi’s decision to terminate its merger with Akorn was legal and proper, Akorn’s COO has agreed to resign the position, six days after Doug Boothe officially replaced Raj Rai as Akorn’s new president and CEO.

Strategy Leadership
See All